NCT01478126View on ClinicalTrials.gov

Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

September 30, 2013

Conditions
Coronary Artery Disease
Interventions
DRUG

N(2)-L-Alanine L-Glutamine dipeptide

Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.

DRUG

Placebo

Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.

Trial Locations (1)

Unknown

State Research Institute of Circulation Pathology, Novosibirsk

All Listed Sponsors
lead

Meshalkin Research Institute of Pathology of Circulation

NETWORK

NCT01478126 - Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass | Biotech Hunter | Biotech Hunter